Cinzia Dello Russo
Affiliations: | catholic University Medical School, Washington, DC, United States |
Area:
Neuroimmunology, microglia, astrocyte, iNOS, EAE, MSGoogle:
"Cinzia Dello Russo"Mean distance: 18.49 (cluster 31) | S | N | B | C | P |
Parents
Sign in to add mentorPierluigi Navarra | grad student | 1997-2001 | catholic University Medical School |
Douglas L. Feinstein | post-doc | 2001-2005 | UIUC |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Dello Russo C, Di Franco V, Tabolacci E, et al. (2023) Remifentanil-induced hyperalgesia in healthy volunteers: a systematic review and meta-analysis of randomized controlled trials. Pain |
Dello Russo C, Cappoli N, Tabolacci E, et al. (2023) Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines. Excli Journal. 22: 295-309 |
Dello Russo C, Navarra P. (2023) What is the weight of expectation bias in oncology trials? British Journal of Clinical Pharmacology |
Dello Russo C, Navarra P. (2022) Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature. Frontiers in Pharmacology. 13: 858354 |
Dello Russo C, Cappoli N, Navarra P. (2020) A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials. European Journal of Clinical Pharmacology |
Cappoli N, Mezzogori D, Tabolacci E, et al. (2019) The mTOR kinase inhibitor rapamycin enhances the expression and release of pro-inflammatory cytokine interleukin 6 modulating the activation of human microglial cells. Excli Journal. 18: 779-798 |
Dello Russo C, Gagliardi D, Ramlogan R, et al. (2019) Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-Small Cell Lung Cancer. Clinical Therapeutics |
Dello Russo C, Cappoli N, Coletta I, et al. (2018) The human microglial HMC3 cell line: where do we stand? A systematic literature review. Journal of Neuroinflammation. 15: 259 |
Lisi L, Ciotti GM, Braun D, et al. (2017) Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma. Neuroscience Letters. 645: 106-112 |
Dello Russo C, Lisi L, Tentori L, et al. (2016) Exploiting Microglial Functions for the Treatment of Glioblastoma. Current Cancer Drug Targets |